Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 12, 2012 | Amylin Seeks to Raise $203M in Stock Offering; Funds Earmarked for Diabetes Drug | Amylin Pharmaceuticals Inc. said March 8 that it expects to raise more than $203 million through a public offering of 13 million shares of its common stock. The San Diego-based biopharmaceutical company plans to use the net proceeds primari... |
| Feb 20, 2012 | Diabetes drug developer Lumena raises $2.5M; compound regulates blood sugar | The Research Triangle Park company is developing a new diabetes treatment based on the role bile acids play as signaling agents in the gastrointestinal tract. When Lumena launched its fundraising efforts last year, CEO Michael Grey explaine... |
| Jun 24, 2011 | Diabetes drug company Lumena raising up to $2M to reach clinical trials | That something else is the diversion of bile. While bile is a means for the body to process fats, it also acts as a signaling agent. In normal gastrointestinal function, most of the bile is recirculated. But gastric bypass surgery also bypa... |
| May 26, 2009 | Shareholder Showdown at Amylin Headquarters | Share Share on Facebook Share on Twitter LinkedIn Email Reprints A battle for control of Amylin Pharmaceuticals (NASDAQ: AMLN) that began last year will come to a final showdown tomorrow at the company’s annual shareholder meeting. Challeng... |
| May 23, 2007 | BioSeek raises $10M from Amylin Pharma for drug screening | BioSeek, a Burlingame, Calif., developer of drug-screening technologies that use human cells, raised $10 million in a third funding round from San Diego-based Amylin Pharmaceuticals. The two companies also formed a partnership in which BioS... |
| Diabetes drug developer Lumena raises $2.5M; compound regulates blood sugar | Diabetes treatment developer Lumena Pharmaceuticals has secured the $2 million it needs to start clinical trials and a little bit extra for good measure. The company’s first round of investment was oversubscribed and led to a haul of $2.5 m... | |
| Diabetes drug company Lumena raising up to $2M to reach clinical trials | Diabetes drug development company Lumena Pharmaceuticals aims to harness a benefit that diabetics receive from gastric bypass surgery and deliver it to those patients in the form of a pill. The Durham, North Carolina-based company plans to ... |
Reviews 0
FAQ about Amylin
What has the press written about Amylin?
Parsers VC has collected 8 articles mentioning Amylin, among them “Amylin Seeks to Raise $203M in Stock Offering; Funds Earmarked for Diabetes Drug” (Mar 12, 2012) and “Diabetes drug developer Lumena raises $2.5M; compound regulates blood sugar” (Feb 20, 2012).
Is Amylin still active?
Yes, Amylin is active; its latest activity on Parsers VC dates from Jun 18, 2025.